Bamco Inc. NY Purchases 475,200 Shares of TherapeuticsMD Inc (TXMD)
Bamco Inc. NY raised its position in TherapeuticsMD Inc (NASDAQ:TXMD) by 126.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 850,000 shares of the company’s stock after buying an additional 475,200 shares during the quarter. Bamco Inc. NY owned 0.42% of TherapeuticsMD worth $4,479,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Bank of New York Mellon Corp grew its holdings in TherapeuticsMD by 12.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 22,892,018 shares of the company’s stock valued at $120,642,000 after buying an additional 2,574,120 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of TherapeuticsMD by 14.3% during the second quarter. JPMorgan Chase & Co. now owns 15,687,509 shares of the company’s stock worth $82,674,000 after buying an additional 1,961,656 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of TherapeuticsMD by 4.4% during the second quarter. Vanguard Group Inc. now owns 10,231,081 shares of the company’s stock worth $53,918,000 after buying an additional 429,211 shares in the last quarter. State Street Corp lifted its holdings in shares of TherapeuticsMD by 6.9% during the first quarter. State Street Corp now owns 3,903,491 shares of the company’s stock worth $28,105,000 after buying an additional 253,237 shares in the last quarter. Finally, Voya Investment Management LLC lifted its holdings in shares of TherapeuticsMD by 33.4% during the second quarter. Voya Investment Management LLC now owns 2,959,107 shares of the company’s stock worth $15,595,000 after buying an additional 741,588 shares in the last quarter.
TherapeuticsMD Inc (NASDAQ TXMD) opened at 5.29 on Monday. The firm has a 50-day moving average price of $6.02 and a 200 day moving average price of $5.58. TherapeuticsMD Inc has a one year low of $3.50 and a one year high of $8.30. The firm’s market capitalization is $1.08 billion.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. The company had revenue of $4.25 million for the quarter, compared to analyst estimates of $4.91 million. TherapeuticsMD had a negative net margin of 462.94% and a negative return on equity of 77.41%. The company’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. Analysts anticipate that TherapeuticsMD Inc will post ($0.43) EPS for the current fiscal year.
A number of brokerages have recently issued reports on TXMD. Jefferies Group LLC set a $15.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, June 14th. Oppenheimer Holdings, Inc. raised shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research report on Tuesday, July 11th. CIBC raised shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research report on Tuesday, July 11th. Zacks Investment Research lowered shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $13.00 price objective on shares of TherapeuticsMD in a research note on Monday, July 17th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $14.88.
In other TherapeuticsMD news, Director Tommy G. Thompson acquired 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The stock was bought at an average cost of $5.99 per share, with a total value of $29,950.00. Following the acquisition, the director now owns 3,555 shares in the company, valued at $21,294.45. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.